HAVCR2 and neoplasm: The authors hypothesized that the normal interaction between TIM3 and TIM3 ligands is immunosuppressive, and the binding of sTIM-3-Ig to TIM3 ligands can block this inhibitory response, thus promoting anti-tumor effects [145].